183 results about "Antigen receptor" patented technology

Disclosed herein are VH-only single domain binders that target claudin 18.2 (CLDN18.2) and chimeric antigen receptors (CARs) that contain the same, engineered T cells containing the CLDN18.2-targeting CARS, and methods of treating cancer (e.g., gastric cancer or pancreatic cancer) using the CAR-T cells.

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The present application relates to the technical field of biology and medicine, and particularly relates to a ULBP2 specific chimeric antigen receptor, a CAR-T cell and application thereof. The ULBP2 specific chimeric antigen receptor comprises a ULBP2 antigen binding domain, a transmembrane domain and an intracellular signaling domain, and the ULBP2 antigen binding domain comprises an amino acid sequence as shown in SEQ ID NO: 1. After the ULBP2 specific chimeric antigen receptor is transduced into lymphocytes, the killing ability of the lymphocytes on tumor cells is significantly enhanced, and the lymphocytes have a significant directional killing effect on tumor cells with high expression of ULBP2. The present application also relates to application of the ULBP2 specific CAR-T cell in combination with an anti-PD1 antibody for treating cancer.

This invention relates to antigen-binding molecules that specifically bind to ALPPL2 and / or ALPP but not ALPL or ALPI. The invention also relates to pharmaceutical compositions, immunoconjugates, and chimeric antigen receptors comprising said antigen-binding molecules. Furthermore, the invention relates to methods for reducing the expression or activity of ALPPL2 in cancer cells, and methods for treating cancer in subjects.

The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising these modified DCs and methods of stimulating an adaptive immune response in a subject. The intracellular domain of the CAR comprises a toll-interleukin receptor (TIL) intracellular signalling domain and a costimulating domain selected from CD3 signalling domain, CD28 signalling domain and a combined CD28 and CD3 signalling domain.

The present invention relates to engineered immune cells expressing a chimeric antigen receptor (anti-mesothelin CAR) specific for mesothelin (MLSN) and their use in the treatment of solid tumors, particularly suitable for allogeneic cell immunotherapy.

The invention relates to an inducible chimeric co-stimulatory receptor (CCR) comprising an intracellular T cell activation dependent localization domain. The invention further relates to an immune cell expressing the inducible CCR, a nucleic acid molecule encoding said inducible CCR, and to a pharmaceutical composition, comprising said immune cell or said nucleic acid molecule. The invention further relates to a method of producing said immune cell and to a method of treating a malignancy, comprising providing immune cells expressing the inducible CCR to a patient in need thereof.

Provided in the present invention is an isolated recombinant nucleic acid molecule, encoding a chimeric antigen receptor (CAR) polypeptide containing a single-chain antibody (scFv) targeting a B7-H3 polypeptide. Further provided are a recombinant vector containing the recombinant nucleic acid molecule, a recombinant T lymphocyte expressing the CAR polypeptide, a method for preparing the recombinant T lymphocyte, a drug for treating cancers that contains the recombinant nucleic acid molecule, recombinant vector, and recombinant T lymphocyte, and the use of the recombinant nucleic acid molecule, recombinant vector, and recombinant T lymphocyte in the treatment of cancers.

This invention discloses an engineered CAR-T cell targeting HIF-1α and its application in tumor immunotherapy. The CAR-T cell expresses a chimeric antigen receptor regulated by the hypoxia-responsive element HRE promoter, with its extracellular domain specifically binding to HIF-1α and its intracellular domain employing the 4-1BB+CD3ζ signaling module. Simultaneously, through immune checkpoint knockout and cytokine / chemokine modification, it achieves hypoxia-dependent activation, anti-exhaustion, high infiltration, and strong killing effects. The CAR-T cells of this invention significantly improve the adaptability to the solid tumor microenvironment and therapeutic efficacy, reduce off-target toxicity, and can be used to prepare drugs for treating malignant tumors such as lung cancer, liver cancer, pancreatic cancer, colorectal cancer, and glioblastoma, possessing significant clinical translational value.

Chimeric antigen receptors (CARs) that bind to Human Leukocyte Antigen (HLA)-pan DP, cells that comprise the CARS and methods of making and using the cells are provided.

The present application relates to a kind of based on logic gate double-target point chimeric antigen receptor modified TIL cell, lentivirus expression vector and application, belong to tumor immunotherapy and gene editing technical field.The TIL cell based on logic gate double-target point chimeric antigen receptor modified in the application, double-target point chimeric antigen receptor includes chimeric antigen receptor EGFR and chimeric antigen receptor GD2;Chimeric antigen receptor EGFR is composed of CD8 alpha signal peptide, anti-EGFR single-chain antibody, CD8 alpha transmembrane region, 4-1BB costimulatory domain and CD3 zeta intracellular signal domain in series;Chimeric antigen receptor GD2 is composed of CD8 alpha signal peptide, anti-GD2 single-chain antibody, CD28 transmembrane region, CD27 costimulatory domain and CD3 zeta intracellular signal domain in series.The present application solves the defects that lentivirus transduction targeting is poor in prior art, CAR signal activation specificity is insufficient, TIL cell is easily exhausted, has the advantages that gene integration is accurate, signal transduction is controllable, in-vivo survival time is long, can be efficiently used for the immunotherapy of double-antigen co-expression solid tumor.

Disclosed herein is a genetically engineered cells expressing a chimeric antigen receptor and methods and uses thereof.

Provided is a bispecific chimeric antigen receptor targeting CD19 and CD22, which comprises extracellular antigen binding domains of heavy-chain variable regions and light-chain variable regions of anti-CD19 and anti-CD22 antibodies. Further provided is a bispecific CAR-T cell targeting CD19 and CD22.

Aspects of the disclosure include methods of treating an autoimmune disease, including reducing the need for chronic immunosuppression, and for effectuating immune reset and / or producing a naive B cell repertoire in a subject in need thereof, the methods comprising administering a therapeutically effective amount of anti-CD20 yδ T cells to the subject, wherein the anti-CD20 yδ T cells express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20.

Provided herein is a composition comprising, a cell, comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains. Also provided herein are methods for treating diseases using the compositions described herein. Further provided herein is a kinase inhibitor for use in therapeutic methods described herein.

Provided are a CD19-targeting humanized antibody and chimeric antigen receptor, and the use thereof. The humanized antibody contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8). The CD19-targeting chimeric antigen receptor contains a CD19-targeting extracellular antigen recognition domain, a hinge region, a transmembrane region, and an intracellular domain, wherein the CD19-targeting extracellular antigen recognition domain contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8).

The application relates to the technical field of biological medicine, in particular to a genetically modified immune cell and construction and application thereof. The genetically modified immune cell expresses a target protein, the target protein comprises a chimeric antigen receptor and a membrane-bound interleukin, the chimeric antigen receptor comprises an antigen binding domain specifically combined with GPC3, and the membrane-bound interleukin comprises a membrane-bound IL-7. The application simultaneously overexpresses the GPC3CAR and the membrane-bound IL-7, improves the killing ability of TILs on tumor cells, simultaneously improves the expansion ability of immune cells in vivo and in vitro, the ability of continuously killing tumors, and is more conducive to improving the treatment effect of immune cells on GPC3-positive tumors.

The present invention provides thymic T regulatory cells (ThyTreg cells) that encode or alternatively express a chimeric antigen receptor (CAR) comprising an extracellular domain, a hinge region, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a cytoplasmic costimulatory domain having a sequence having at least 85% identity with SEQ ID NO: 1, and a cytoplasmic stimulatory domain. The present invention also provides compositions and uses in immunotherapy.

This article provides a CD79b antibody and a CD79b-specific chimeric antigen receptor (CAR). Further, this article provides immune cells expressing the CD79b-specific CAR and a method for treating cancer by administering the CD79b-specific CAR immune cells.

The application belongs to the field of biological medicine, and relates to a lipid component of a chimeric antigen receptor neutrophil targeting Her2 generated in vivo, a preparation method thereof and application in solid tumor treatment. The lipid nanoparticle is a double-targeted lipid nanoparticle, and the double targeting is realized by Ly6G antibody fragments and NEBP polypeptides. The lipid nanoparticle comprises a lipid component and mRNA encoding Her2-CAR and IFN-gamma. The mRNA encoding Her2-CAR and IFN-gamma is delivered by the lipid nanoparticle LNP, and is delivered to neutrophils in vivo and expresses Her2-CAR and IFN-gamma to generate CAR-neutrophils, so that the cumbersome step of editing immune cells in vitro is omitted, and potential adverse reactions caused by reinfusion of CAR-immune cells prepared in vitro into the body are avoided.

This invention provides a bispecific chimeric antigen receptor targeting BCMA-CD19 and its application, wherein the bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain; wherein: the extracellular antigen recognition domain comprises an anti-BCMA extracellular antigen recognition domain and an anti-CD19 extracellular antigen recognition domain; the anti-CD19 extracellular antigen recognition domain comprises CD19VH and CD19VL, which are selected from one of groups 1) to 8).

The present disclosure relates in some aspects to methods for analyzing antigen receptor transcripts in a biological sample. In some aspects, nucleic acid molecules are generated from V(D)J transcripts in situ in the biological sample to enrich molecules comprising V(D)J joins. In some aspects, the presence, amount, and / or identity of a plurality of V(D)J transcripts are analyzed in situ. Also provided are oligonucleotides, sets of oligonucleotides, compositions, and kits for use in accordance with the methods.

A nanoparticle for treating hepatocellular carcinoma (HCC) in which the nanoparticle includes a lipid phase and a core that contains one or more nucleic acids encoding a chimeric antigen receptor (CAR), a T-cell engager (TCE), and / or a therapeutic gene. The CAR and the TCE each binding specifically to an HCC tumor-associated antigen and the nanoparticle selectively delivers the one or more nucleic acids to M2 macrophages in vitro and in vivo. Also provided is a therapeutic composition that contains a plurality of the nanoparticle described above and a pharmaceutically acceptable excipient. Further provided are methods for converting HCC tumor-resident M2 macrophages into M1 macrophages, and for treating HCC.

Disclosed herein are engineered polyfunctional CD4+ T cells / CAR T cells and methods of their use for the treatment of cancers. One embodiment provides a method of producing polyfunctional CD4+ T cells by constitutively activating STAT5A in the cells to induce a polyfunctional phenotype. Also provided is a method of reversing exhaustion in tumor-specific CD4+ T cells by engineering the cells to express Fos, Jun, Nr4a1, or combinations thereof but not express Tox, Pdcd1, Ctla4, Haver2, Lag3, Tigit, Slam6, Nrf4a2, and administering the engineered cells to a subject.

The invention relates to a chimeric antigen receptor based on a functional fragment of an MAVS protein, in particular to a chimeric antigen receptor (CAR) construct positioned on a cell membrane, and an intracellular structural domain of the CAR construct contains the functional fragment derived from the MAVS protein. The MAVS protein is a truncated body with deletion or mutation of a mitochondrial positioning region of the MAVS protein. The engineered immune cell for expressing the CAR construct disclosed by the invention has specific targeting property and a remarkable anti-tumor effect.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) or allograft rejection in subjects receiving donor cells. Also disclosed are methods enhancing regulatory T (Treg) cells for use in preventing GVHD. Also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the treated Treg cells. Also disclosed are enhanced Treg cells produced by the disclosed methods that have been engineered to express chimeric antigen receptor (CAR) polypeptide cells.

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

The present invention provides an anti-BAFFR antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a carrier containing the nucleic acid molecule, a host cell containing the nucleic acid molecule or the carrier, an antibody conjugate containing the antibody molecule, a chimeric antigen receptor, a pharmaceutical composition and a cassette, and their use in the preparation of a medicament for treating cancer or an autoimmune disease.